secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000313143-25-000015
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO
----------------------------------------------------------------------

- Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.
- Roy Galvin promoted to EVP, Chief Commercial Officer effective immediately; adds Global Hospital business to his remit.
- Chan's compensation: $550k base salary, 80% target bonus, $1.6M long-term equity award, plus $350k sign-on bonus.
- Chan most recently President of Medtronic's Acute Care & Monitoring business; 25+ years experience.
- Stewart Strong continues as President, Global Hospital through April 1, then advisor to CEO for transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/0000313143-25-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/hae-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000313143-25-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer